Zanubrutinib maintenance for DLBCL patients in remission
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a pill called zanubrutinib as a follow-up treatment for people with DLBCL (a type of blood cancer) who are too frail or older to receive more intensive chemotherapy but whose cancer has already shrunk after initial treatment. The goal is to see if this maintenance therapy helps keep the cancer in remission and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a type of lymphoma called DLBCL that improved or disappeared after your first treatment.
- You were not able to tolerate standard chemotherapy (like R-CHOP) because of side effects or because you are older or frail.
- You are physically active enough to be up and about (ECOG score 0-2).
- Doctors expect you to live more than 3 months.
- Your blood counts and liver/kidney function are within safe ranges for this study.
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.